Market Research Report
Primary Sclerosing Cholangitis - Pipeline Review, H1 2019
|Published by||Global Markets Direct||Product code||246021|
|Published||Content info||115 Pages
Delivery time: 1-2 business days
|Primary Sclerosing Cholangitis - Pipeline Review, H1 2019|
|Published: February 1, 2019||Content info: 115 Pages||
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides an overview of the Primary Sclerosing Cholangitis (Gastrointestinal) pipeline landscape.
Primary sclerosing cholangitis (PSC) is a chronic liver disease characterized by a progressive course of cholestasis with inflammation and fibrosis of the intrahepatic and extra hepatic bile ducts. Symptoms include abdominal pain, chills, diarrhea, fatigue, itchiness and weight loss. The predisposing factors include age and inflammatory bowel diseases. Treatment includes antibiotics and bile-acid-binding drugs.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Primary Sclerosing Cholangitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Primary Sclerosing Cholangitis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Sclerosing Cholangitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 8, 2, 11 and 1 respectively.
Primary Sclerosing Cholangitis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.